palomid 529,
RES-529,
Palomid 529,
914913-88-5,
P529,
Palomid 529 (P529),
8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one,
Palomid-529,
P-529,
Palomid529,
SG 00529,
SG-00529,
AK160239,
8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one,
C24H22O6,
UNII-XV9409EWG4,
6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-,
8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one,
8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one,
6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-,
8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one,
XV9409EWG4,
Palomid 529,P529,
Palomid-529-P529,
MLS006011187,
Palomid 529 - P529,
SCHEMBL290034,
C22H26Cl2N2O8,
CHEMBL2141712,
EX-A254,
QCR-215,
SYN5215,
BCPP000131,
HMS3655L14,
BCP02474,
ABP000907,
MFCD18633224,
s2238,
8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one,
AKOS024463339,
ACN-030389,
API0010433,
BCP9001049,
CS-0258,
DB12812,
Palomid 529 (P529) /P529,
RL05762,
SB16564,
NCGC00263125-01,
AS-16573,
BC638799,
HY-14581,
SC-96654,
SMR004702956,
AB0008147,
AX8293417,
P 529,
ST24045740,
SW219676-1,
Y0291,
W-5766,
J-519339,
P529, 914913-88-5,
P-529|||8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one,
Palomid529(P529),
cc-513,
RES-529,
CID11998575,
CID 11998575,
C533469,
Palomid 529, 98%, a novel potent inhibitor of both the mTORC1 and mTORC2 - 10MG 10mg,
8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one PaloMid 529 (P529),